Get started
bluebird bio, Inc.bluebird bio, Inc.bluebird bio, Inc.

bluebird bio, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

BLUE chart


Full chart

BLUE upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪40.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−24.86 USD
Net income (FY)
‪−240.72 M‬ USD
Revenue (FY)
‪83.81 M‬ USD
Shares float
‪9.68 M‬
Beta (1Y)
−0.091

Employees


Employees (FY)
248
Change (1Y)
−127 −33.87%
Revenue / Employee (1Y)
‪337.93 K‬ USD
Net income / Employee (1Y)
‪−970.63 K‬ USD

About bluebird bio, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Andrew Obenshain
Website
bluebirdbio.com
Headquarters
Somerville
Founded
1992
FIGI
BBG000QGWY50
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BLUE news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BLUE.

Frequently Asked Questions


The current price of BLUE is 4.14 USD — it has decreased by −0.24% in the past 24 hours. Watch bluebird bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange bluebird bio, Inc. stocks are traded under the ticker BLUE.
BLUE stock has fallen by −14.64% compared to the previous week, the month change is a 4.81% rise, over the last year bluebird bio, Inc. has showed a −78.44% decrease.
We've gathered analysts' opinions on bluebird bio, Inc. future price: according to them, BLUE price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch BLUE chart and read a more detailed bluebird bio, Inc. stock forecast: see what analysts think of bluebird bio, Inc. and suggest that you do with its stocks.
BLUE reached its all-time high on Mar 13, 2018 with the price of 3,057.66 USD, and its all-time low was 3.56 USD and was reached on Feb 24, 2025. View more price dynamics on BLUE chart.
See other stocks reaching their highest and lowest prices.
BLUE stock is 2.91% volatile and has beta coefficient of −0.091. Track bluebird bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is bluebird bio, Inc. there?
Today bluebird bio, Inc. has the market capitalization of ‪40.53 M‬, it has decreased by −7.84% over the last week.
Yes, you can track bluebird bio, Inc. financials in yearly and quarterly reports right on TradingView.
bluebird bio, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
BLUE earnings for the last quarter are −4.75 USD per share, whereas the estimation was −6.15 USD resulting in a 22.75% surprise. The estimated earnings for the next quarter are −3.29 USD per share. See more details about bluebird bio, Inc. earnings.
bluebird bio, Inc. revenue for the last quarter amounts to ‪25.25 M‬ USD, despite the estimated figure of ‪27.20 M‬ USD. In the next quarter, revenue is expected to reach ‪38.74 M‬ USD.
BLUE net income for the last quarter is ‪−28.71 M‬ USD, while the quarter before that showed ‪−60.81 M‬ USD of net income which accounts for 52.78% change. Track more bluebird bio, Inc. financial stats to get the full picture.
No, BLUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 248 employees. See our rating of the largest employees — is bluebird bio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. bluebird bio, Inc. EBITDA is ‪−206.46 M‬ USD, and current EBITDA margin is −246.35%. See more stats in bluebird bio, Inc. financial statements.
Like other stocks, BLUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade bluebird bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So bluebird bio, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating bluebird bio, Inc. stock shows the sell signal. See more of bluebird bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.